The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli CohortTal Grenader, David Geffen, Rinat Yerushalmi et al.|Oncology|2014Cited by 44
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapySalomon M. Stemmer, David Geffen, Mariana Steiner et al.|npj Breast Cancer|2019Cited by 30
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain MetastasesDebu Tripathy, Cláudia Vieira, Javier Cortés et al.|JAMA Oncology|2022Cited by 24
Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorizationSalomon M. Stemmer, S. Shak, Michelle Leviov et al.|The Breast|2019Cited by 2
Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysisGil Bar‐Sela, Salomon M. Stemmer, Samih Yousef et al.|The Breast Journal|2020Cited by 2